From USFDA
Aurobindo Pharma has received tentative approval from USFDA under U.S. President's Emergency Plan for AIDS Relief for its New Drug Application for Dolutegravir, Lamivudine & Tenofovir Disoproxil Fumarate tablets, 50 mg/ 300 mg/ 300mg. The triple combination product is expected to be launched in sub-Saharan Africa in Q3 FY 2018.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
